Using FAIMS to improve tumor neoantigen detection
Ontology highlight
ABSTRACT:
INSTRUMENT(S): Orbitrap Fusion Lumos
ORGANISM(S): Mus Musculus (ncbitaxon:10090)
SUBMITTER: 
Robert Schreiber Cheryl Lichti
PROVIDER: MSV000092617 | MassIVE | Tue Aug 08 07:33:00 BST 2023
SECONDARY ACCESSION(S): PXD044450
REPOSITORIES: MassIVE
Publications
Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry.
Meng Wei W Takeuchi Yoshiko Y Ward Jeffrey P JP Sultan Hussein H Arthur Cora D CD Mardis Elaine R ER Artyomov Maxim N MN Lichti Cheryl F CF Schreiber Robert D RD
Cancer immunology research 20240801 8
Cancer neoantigens have been shown to elicit cancer-specific T-cell responses and have garnered much attention for their roles in both spontaneous and therapeutically induced antitumor responses. Mass spectrometry (MS) profiling of tumor immunopeptidomes has been used, in part, to identify MHC-bound mutant neoantigen ligands. However, under standard conditions, MS-based detection of such rare but clinically relevant neoantigens is relatively insensitive, requiring 300 million cells or more. Here ...[more]
Similar Datasets
Project description:Immunoglobulin gene rearrangement and somatic hypermutation have the potential to create neoantigens in non-Hodgkin B cell lymphoma. However, the presentation of these putative immunoglobulin neoantigens by B cell lymphomas has not been proven. We used MHC immunoprecipitation followed by liquid chromatography and tandem mass spectrometry (LC-MS/MS) to define antigens presented by follicular lymphomas (FL), chronic lymphocytic leukemias (CLL), diffuse large B cell lymphoma (DLBCL) and mantle cell lymphomas (MCL). We found presentation of the clonal immunoglobulin molecule, including neoantigens by both class I and class II MHC, though more commonly in class II MHC. To determine whether B cell activation could promote presentation of immunoglobulin neoantigens, we used a toll-like receptor 9 (TLR9) agonists to upregulate expression of MHC-II. This resulted in enhanced class II MHC presentation of the immunoglobulin variable region including neoantigens. These findings demonstrate that immunoglobulin neoantigens are presented across most subtypes of B cell lymphomas. Activation of lymphoma cells to upregulate antigen presentation boosts presentation of immunoglobulin neoantigens and represents a strategy for augmenting lymphoma immunotherapies.
2019-01-07 | PXD010808 | Pride
Project description:This study was to predict neoantigens in 1956 and F244 murine MCA-sarcomas (female C57BL/6N and male 129S6 lines, respectively). Mutations were called by comparing tumor versus normal whole exome sequencing (WES) data, and filtered for expressing mutations using RNA-seq data. Out of expressing mutations, MHC class I or II neoantigens were predicted and screened by T cell reactivities (IFN-gamma ELISPOT and tetramer staining). Therapeutic vaccine confirmed an M50I mutation in Psmd6 and an R144S mutation in Cs to be the major MHC class I (H-2Kb) and II (I-Ab) neoantigens for 1956; and a G122A in Pex14 and a D2944Y mutation in Plec to be the major class I (H-2Kb) and class II (I-Ab) neoantigens for F244.
2024-05-20 | GSE267886 | GEO
Project description:The analysis of complex protein mixtures, such as FFPE tissue or plasma exosomes samples, is a challenge nowadays due to the low proteome coverage achieved by mass spectrometers nowadays. We have here investigated the benefits of FAIMS technology coupled to the Orbitrap Exploris 480 mass spectrometer for the TMT quantitative proteomics analyses of these complex samples, in comparison to easy-to-work cell protein extracts. A two-hours gradient LC-MS/MS without or with FAIMS and two compensation voltages (CV=-45 and CV=-60) was used for the analysis. Although a slightly increase in the number of identified and quantified proteins was associated to a decrease in the number of identified and quantified peptides with FAIMS in the cell protein extract TMT experiment, we observed a significant improvement (>100%) in the number of peptide and protein identifications and quantifications for the plasma exosomes and FFPE tissue samples TMT experiments with FAIMS in comparison to the LC-MS/MS analysis without FAIMS. Our results highlight the potential of mass spectrometry analyses with FAIMS to increase the depth into the proteome of complex samples as FFPE and plasma-derived exosomes, which might aid in the characterization of their proteome and proteoforms and in the identification of dysregulated proteins that could be used as biomarkers.
2024-01-26 | PXD042597 | Pride
Project description:The analysis of complex protein mixtures, such as FFPE tissue or plasma exosomes samples, is a challenge nowadays due to the low proteome coverage achieved by mass spectrometers nowadays. We have here investigated the benefits of FAIMS technology coupled to the Orbitrap Exploris 480 mass spectrometer for the TMT quantitative proteomics analyses of these complex samples, in comparison to easy-to-work cell protein extracts. A two-hours gradient LC-MS/MS without or with FAIMS and two compensation voltages (CV=-45 and CV=-60) was used for the analysis. Although a slightly increase in the number of identified and quantified proteins was associated to a decrease in the number of identified and quantified peptides with FAIMS in the cell protein extract TMT experiment, we observed a significant improvement (>100%) in the number of peptide and protein identifications and quantifications for the plasma exosomes and FFPE tissue samples TMT experiments with FAIMS in comparison to the LC-MS/MS analysis without FAIMS. Our results highlight the potential of mass spectrometry analyses with FAIMS to increase the depth into the proteome of complex samples as FFPE and plasma-derived exosomes, which might aid in the characterization of their proteome and proteoforms and in the identification of dysregulated proteins that could be used as biomarkers.
2024-01-26 | PXD042596 | Pride
Project description:The analysis of complex protein mixtures, such as FFPE tissue or plasma exosomes samples, is a challenge nowadays due to the low proteome coverage achieved by mass spectrometers nowadays. We have here investigated the benefits of FAIMS technology coupled to the Orbitrap Exploris 480 mass spectrometer for the TMT quantitative proteomics analyses of these complex samples, in comparison to easy-to-work cell protein extracts. A two-hours gradient LC-MS/MS without or with FAIMS and two compensation voltages (CV=-45 and CV=-60) was used for the analysis. Although a slightly increase in the number of identified and quantified proteins was associated to a decrease in the number of identified and quantified peptides with FAIMS in the cell protein extract TMT experiment, we observed a significant improvement (>100%) in the number of peptide and protein identifications and quantifications for the plasma exosomes and FFPE tissue samples TMT experiments with FAIMS in comparison to the LC-MS/MS analysis without FAIMS. Our results highlight the potential of mass spectrometry analyses with FAIMS to increase the depth into the proteome of complex samples as FFPE and plasma-derived exosomes, which might aid in the characterization of their proteome and proteoforms and in the identification of dysregulated proteins that could be used as biomarkers.
2024-01-26 | PXD042601 | Pride
Project description:Whole Genome Sequencing of the murine breast cancer cell line 4T1 and of the murine melanoma cell line B16-ova was carried out with the aim of identifying somatic mutations. We also ran deep Mass Spectrometry proteomics analysis on the same cell lines, aiming to determine which somatic mutations carry over to the protein expression level. Further, we tested these cancer specific protein epitopes (putative neoantigens) for immunogenicity using mouse models. Finally, the putative neoantigens that showed good immunogenic potential were used in tumor growth control experiments with mice engrafted with the two tumor cell lines. In these experiments we tested whether cancer vaccines based on individual neoantigen peptides (MHC-I) restricted the growth of the tumor compared to adequate controls. The overall aim of the project is to validate the ability of our multi-omics/bioinformatics pipeline to identify and deliver neoantigens that can be used to suppress tumor growth. File names Sample names P10859_101_S1_L001_R1_001_BHKWV3CCXY 4T1_S1_L001_R1_001_BHKWV3CCXY P10859_101_S1_L001_R2_001_BHKWV3CCXY 4T1_S1_L001_R2_001_BHKWV3CCXY P10859_101_S1_L002_R1_001_BHKWV3CCXY 4T1_S1_L002_R1_001_BHKWV3CCXY P10859_101_S1_L002_R2_001_BHKWV3CCXY 4T1_S1_L002_R2_001_BHKWV3CCXY P10859_102_S2_L003_R1_001_BHKWV3CCXY B16-OVA_S2_L003_R1_001_BHKWV3CCXY P10859_102_S2_L003_R2_001_BHKWV3CCXY B16-OVA_S2_L003_R2_001_BHKWV3CCXY P10859_102_S2_L004_R1_001_BHKWV3CCXY B16-OVA_S2_L004_R1_001_BHKWV3CCXY P10859_102_S2_L004_R2_001_BHKWV3CCXY B16-OVA_S2_L004_R2_001_BHKWV3CCXY
2024-01-31 | E-MTAB-13635 | biostudies-arrayexpress
Project description:RNA Sequencing of the murine breast cancer cell line 4T1 and of the murine melanoma cell line B16-ova was carried out with the aim of establishing the complete transcriptome of these cell lines. Because these are cancer cells and we expect a lot of aberrant splicing, we carried out de novo assembly (genome guided) of the transcripts. We also ran deep Mass Spectrometry proteomics analysis on the same cell lines, aiming to determine which aberrant transcripts carry over to the protein expression level. Further, we tested these cancer specific protein epitopes (putative neoantigens) for immunogenicity using mouse models. Finally, the putative neoantigens that showed good immunogenic potential were used in tumor growth control experiments with mice engrafted with the two tumor cell lines. In these experiments we tested whether cancer vaccines based on individual neoantigen peptides (MHC-I) restricted the growth of the tumor compared to adequate controls. The overall aim of the project is to validate the ability of our multi-omics/bioinformatics pipeline to identify and deliver neoantigens that can be used to suppress tumor growth.
2024-06-30 | E-MTAB-14130 | biostudies-arrayexpress
Project description:The analysis of complex protein mixtures, such as FFPE tissue or plasma exosomes samples, is a challenge nowadays due to the low proteome coverage achieved by mass spectrometers nowadays. We have here investigated the benefits of FAIMS technology coupled to the Orbitrap Exploris 480 mass spectrometer for the TMT quantitative proteomics analyses of these complex samples, in comparison to easy-to-work cell protein extracts. A two-hours gradient LC-MS/MS without or with FAIMS and two compensation voltages (CV=-45 and CV=-60) was used for the analysis. Although a slightly increase in the number of identified and quantified proteins was associated to a decrease in the number of identified and quantified peptides with FAIMS in the cell protein extract TMT experiment, we observed a significant improvement (>100%) in the number of peptide and protein identifications and quantifications for the plasma exosomes and FFPE tissue samples TMT experiments with FAIMS in comparison to the LC-MS/MS analysis without FAIMS. Our results highlight the potential of mass spectrometry analyses with FAIMS to increase the depth into the proteome of complex samples as FFPE and plasma-derived exosomes, which might aid in the characterization of their proteome and proteoforms and in the identification of dysregulated proteins that could be used as biomarkers.
2024-01-26 | PXD045367 | Pride
Project description:The analysis of complex protein mixtures, such as FFPE tissue or plasma exosomes samples, is a challenge nowadays due to the low proteome coverage achieved by mass spectrometers nowadays. We have here investigated the benefits of FAIMS technology coupled to the Orbitrap Exploris 480 mass spectrometer for the TMT quantitative proteomics analyses of these complex samples, in comparison to easy-to-work cell protein extracts. A two-hours gradient LC-MS/MS without or with FAIMS and two compensation voltages (CV=-45 and CV=-60) was used for the analysis. Although a slightly increase in the number of identified and quantified proteins was associated to a decrease in the number of identified and quantified peptides with FAIMS in the cell protein extract TMT experiment, we observed a significant improvement (>100%) in the number of peptide and protein identifications and quantifications for the plasma exosomes and FFPE tissue samples TMT experiments with FAIMS in comparison to the LC-MS/MS analysis without FAIMS. Our results highlight the potential of mass spectrometry analyses with FAIMS to increase the depth into the proteome of complex samples as FFPE and plasma-derived exosomes, which might aid in the characterization of their proteome and proteoforms and in the identification of dysregulated proteins that could be used as biomarkers.
2024-01-26 | PXD045362 | Pride
Project description:Cancer somatic mutations can generate neoantigens that distinguish malignant from normal cells. Such neoantigens have been implicated in response to immunotherapies including immune checkpoint blockade, yet their identification and validation remains challenging. Here we discover neoantigens in human mantle cell lymphomas using an integrated strategy for genomic and proteomic tumor antigen discovery that interrogates peptides presented within the tumor major histocompatibility complex (MHC) class I and class II molecules. We applied this approach to systematically identify neoantigen peptides in diagnostic tumor specimens from 17 patients. Remarkably, the 52 discovered neoantigenic peptides were invariably derived from the lymphoma immunoglobulin (Ig) heavy or light chain variable regions. Although we could identify MHC presentation of private germline polymorphic alleles, no mutated peptides were recovered from non-Ig somatically mutated genes. The immunoglobulin variable region somatic mutations were almost exclusively presented by MHC-II. We found T-cells specific for an immunoglobulin-derived neoantigen in the blood of a patient using MHC-II tetramers, and these T-cell clones expanded in frequency following tumor vaccination. These results demonstrate that an integrative approach combining MHC isolation, peptide identification and exome sequencing is an effective platform to uncover tumor neoantigens. Application of this strategy to human lymphoma implicates immunoglobulin neoantigens as targets for lymphoma immunotherapy.
2017-03-27 | PXD004746 | Pride